Corcept Therapeutics (CORT) Cash & Equivalents (2010 - 2026)
Corcept Therapeutics (CORT) posted Cash & Equivalents of $111.0 million for Q2 2026, up 2.12% sequentially from $108.7 million in Q1 2026, and up 8.07% YoY from $102.7 million in Q2 2025.
Corcept Therapeutics (CORT) Cash & Equivalents (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Cash & Equivalents for 17 years, with the latest figure at $111.0 million in Q2 2026.
- Quarterly Cash & Equivalents rose 8.07% year-over-year to $111.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $111.0 million (up 8.07% YoY) and the FY2025 annual result came in at $120.5 million, down 5.62% from the prior year.
- Cash & Equivalents rose to $111.0 million in Q2 2026 per CORT's latest filing, from $108.7 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $299.9 million in Q1 2023 and troughed at $35.3 million in Q2 2022.
- A 5-year average of $118.6 million and a median of $116.1 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 62.96% in 2022, then surged 387.68% in 2023.
- Over 5 years, Cash & Equivalents stood at $66.3 million in 2022, then soared by 104.36% to $135.6 million in 2023, then dropped by 5.82% to $127.7 million in 2024, then declined by 5.62% to $120.5 million in 2025, then dropped by 7.85% to $111.0 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $111.0 million, $108.7 million, and $120.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 111.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 111.04 Mn |
| Mar 31, 2026 | 108.74 Mn |
| Dec 31, 2025 | 120.50 Mn |
| Sep 30, 2025 | 125.14 Mn |
| Jun 30, 2025 | 102.75 Mn |
| Mar 31, 2025 | 89.82 Mn |
| Dec 31, 2024 | 127.67 Mn |
| Sep 30, 2024 | 137.29 Mn |
| Jun 30, 2024 | 128.59 Mn |
| Mar 31, 2024 | 149.75 Mn |
| Dec 31, 2023 | 135.55 Mn |
| Sep 30, 2023 | 111.80 Mn |
| Jun 30, 2023 | 172.38 Mn |
| Mar 31, 2023 | 299.94 Mn |
| Dec 31, 2022 | 66.33 Mn |
| Sep 30, 2022 | 50.24 Mn |
| Jun 30, 2022 | 35.35 Mn |
| Mar 31, 2022 | 61.86 Mn |
| Dec 31, 2021 | 77.62 Mn |
| Sep 30, 2021 | 94.69 Mn |